An observational study in Type 2 Diabetes and Circadian Rhythm, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-07.
Sponsored by Steno Diabetes Center Copenhagen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 8 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one is one of 4 that started in 2024, is one of 6 observational ones, and was the 21st registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →8 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18–74
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 65+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 50 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 94 across the 24 interventional studies, 148 across the 6 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.
3 of the studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262788Steno Diabetes Center CopenhagenA Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes | 2027-03 |
| NCT07645079Steno Diabetes Center CopenhagenAutomated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care | 2027-07-15 |
| NCT07641309Steno Diabetes Center CopenhagenMeasurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the present clinical descriptive study is to characterize and quantify the potential hormonal chronobiological differences between individuals with type 2 diabetes (T2D) and healthy age and weight-matched controls as either circadian aligned or misaligned. The investigators hypothesize that individuals with T2D have a misaligned and different circadian rhythmicity of circadian biomarkers (melatonin and cortisol) than controls, and that this difference in turn is related to 24h hormonal fluctuations, behaviour, and metabolic-, cardiac-, and cognitive parameters.
Participants will be asked to:
T2D is associated with cognitive dysfunction and an increased risk of developing dementia. This negative effect on cognition is worsened by T2D duration, yet the mechanisms are unknown.
Sleep disturbances increase peripheral insulin resistance, and is associated with the development of T2D, temporarily worsened cognitive function, and the development of cognitive impairment. In turn, T2D is associated with circadian misalignment (a condition where the internal physiological clock is unaligned with the external behavior). A major external signal (also known as zeitgeber) for synchronizing the internal and external clock is sleep in accordance with the day-night cycle.
Determining the circadian rhythm of an individual and whether it is aligned or misaligned is complex and can't be done by one measurement. However, melatonin and cortisol are often used as "circadian biomarkers" due to significant and well-defined circadian rhythm profiles. Another measure of the circadian phase is the timing of melatonin production under dim light conditions (dim light melatonin onset) which is an individual phase marker depending on the persons habitual time of sleep. Most studies focusing on circadian alignment in an everyday setting have used questionnaires, and to our knowledge, no studies have described 24-h circadian oscillations between individuals with T2D and healthy age and weight matched controls. Mapping these potential differences could help explain the pathophysiological mechanisms behind T2D and circadian misalignment.
The Cir-D-Brain study is a clinical descriptive study. The study comprises of an information visit, a screening visit, a midway visit (2 weeks after screening), a 24-h in-hospital day (a day between the midway visit and the final visit), and a final visit (2 weeks after the midway visit). Participants will keep a diary on eating and sleeping habits for all 30 days. At the midway visit, participants will be equipped with an actigraphy and a continuous glucose monitor. At the 24-h in-hospital day, participants will have their blood sampled every third hour for 24 hours to measure their circadian rhythm, every hour from 6 pm till 12 am to map dim light melatonin onset, and at wake-up to map cortisol awakening response. At the 24-h in-hospital day, participants will furthermore have their sleep stages measured by polysomnography. The study will include 30 participants with T2D and 30 age and BMI matched controls.
The specific objectives are:
Primary care clinic, Steno Diabetes Center Copenhagen out-patient clinic, community sample
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals with T2D:
Healthy matched controls:
Exclusion Criteria:
Cardiac problems including any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with type 2 diabetes
Individuals without type 2 diabetes matched on age and body mass index
Melatonin oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Cortisol oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Dim light melatonin onset
Blood samples (pg/ml)
Time frame: 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)
Phase angle (time between dim light melatonin onset and sleep)
Blood samples
Time frame: 24-hour in-hospital day, blood samples taken every hour from 18:00 until 00:00 (7 timepoints in total)
Cortisol awakening response
Blood samples (pg/ml)
Time frame: 24-hour in-hospital day, blood samples taken at wake up, and 15-, 30-, and 60-minutes post-wake up
Diary on sleeping habits
Expanded Consensus Sleep Diary (time in bed, time to fall asleep, number of awakenings and durations, time of final awakening, time to get out of bed, total sleep time, sleep quality, daytime sleepiness, number of naps and duration, number and last time of alcohol consumption, number and last time of coffein consumption, use of sleep medicine)
Time frame: 30 days
Diary on eating window
The eating window (initiation of first consumption and termination of last consumption of food)
Time frame: 30 days
Glycaemic variability
Continuous glucose monitor (amplitude (mmol/L), frequency, and duration of the fluctuation, mean glucose (mmol/L), time in range, time in hyperglycemic and hypoglycemic range, area under the curve)
Time frame: 10-14 days
Sleep and waking states
Actrigraph worn on the wrist of the non-dominant hand (acceleration at different times)
Time frame: 10-14 days
Heart rate variability (fluctuations in time intervals between adjacent heart beats)
Measured continuously by the polysomnograph (ms)
Time frame: 24-hour in-hospital day
Sleep architecture
Polysomnography (minutes and percentages). Sleep stages (N1, N2, N3, rapid eye movement (REM)), total time asleep, sleep latency, REM sleep latency, arousals, awakenings, total sleep efficiency.
Time frame: 24-hour in-hospital day
Cognition (verbal memory)
Rey Auditory Verbal Learning Test (RAVLT)
Time frame: 24-hour in-hospital day
Cognition (psychomotor speed and executive function)
Trail Making Test (TMT) part A and B ), Symbol Digit Modalities Test (SDMT)
Time frame: 24-hour in-hospital day
Cognition (executive function)
WAIS-III Letter-Number Sequencing test, Verbal fluency test (letters S and D)
Time frame: 24-hour in-hospital day
Cognition (sustained attention)
Rapid Visual Processing (RVP) test from the Cambridge Neuropsychological Test Automated Battery (CANTAB)
Time frame: 24-hour in-hospital day
Cognition (verbal IQ)
Danish Adult Reading Test (DART) (equivalent to the National Adult Reading Test; NART)
Time frame: 24-hour in-hospital day
Insulin oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
C-peptide oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
TSH oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Glucose oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Glucagon oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Glucagon-like peptide-1 (GLP-1) oscillations (amplitude, peak, mesor, phase, period length (TAU))
Blood samples.
Time frame: 24-hour in-hospital day, blood samples taken every third hour for 24 hours (9 timepoints in total)
Chronotype (diurnal preference)
Morningness-Eveningness Questionnaire (scoring)
Time frame: At screening
Sleep apnea
Apnea-hypopnea index (events/hour)
Time frame: 24-hour in-hospital day
Blood pressure variations
Measured continuously by the polysomnograph (mmHg)
Time frame: 24-hour in-hospital day
Cardiovascular autonomic neuropathy
Assessed from three standard cardiovascular autonomic reflex tests: lying-to-standing test, deep breathing test, and Valsalva manoeuvre
Time frame: At screening
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for May 2025, 15 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Steno Diabetes Center Copenhagen →